EchoSense Ltd. is a privately held company founded in 2006 by Professor Yoram Palti and Lennart Perlhagen. The company develops innovative ultrasound Doppler systems and introduced the developed the first fully automatic signal processing and classification packages for diagnosis of various Cardiac and Pulmonary diseases.
EchoSense diagnosis and patient monitoring technology has undergone extensive clinical trials in the United States, Europe and in Israel. EchoSense technology is ISO certified and has acquired CE approval for peripheral blood flow measurements. The company expects to make FDA and additional CE submissions, for various cardio-pulmonary diagnoses during 2017.
EchoSense develops innovative ultrasound doppler technology to enable fast, simple and reliable diagnosis of heart and lung diseases to improve the health of millions of people worldwide.
Select a profile for more information.
Professor Yoram Palti is Professor Emeritus of Physiology & Biophysics and Biomedical Engineering at the Technion, Israel Institute of Technology. Professor Palti served for 12 years as head of the Rappaport Institute for Research in the Medical Sciences, the medical research arm of the Technion. He has founded and managed several startup companies (including Interspark, Carmel Biosensor, NovoCure) dedicated to the development of medical equipment. Professor Palti has over 50 registered US patents and is the author of more than 80 papers in reputable scientific journals and publications.
Lennart Perlhagen is a serial entrepreneur and investor in emerging healthcare companies. He is a founding investor in NovoCure and founded Meda AB, a leading specialty pharmaceutical company based in Sweden. During his tenure at Meda AB, the company grew from a market capitalization of $10 million to over $4.0 billion. Prior to Meda AB, Lennart was the CEO for Scandinavia and UK for Pharmitalia Spa (later acquired by Pfizer) where he gained extensive experience in oncology through the launch of the chemotherapy agent doxorubicin (Adriamycin). Lennart also helped lead the commercial launch of Omeprazole (Losec/Prilosec), which became the best-selling pharmaceutical product in the world for Astra AB where he served as Regional Director for South Europe and as a member of the Marketing Strategy Group.
Bob joined EchoSense in 2016 after 30+ years with Johnson and Johnson. He has extensive business development experience across the pharmaceutical, consumer and medical device sectors within J&J. Most recently Bob was Vice President Global Business Development responsible for licensing, acquisition and joint venture activity. Bob has a BS in Accounting from Villanova University and is a CPA (inactive) and is located in Philadelphia, PA.
Dr. Rachel Schatzberger began her academic career as a Researcher at Stanford University in 1985 and assumed the position of Senior Researcher in Electrophysiology & Biophysics at the Technion in 1987. In 1993, she joined Carmel Biosensors Ltd, Israel as Head of Electrophysiology and later served as Project Manager and Manager of Regulation & Clinical Trials. In 2002, she assumed the position of Manager of Regulation Affairs & Clinical Trials at NovoCure Ltd, Israel. She was appointed CSO at EchoSense in 2008. Rachel holds a D.Sc. degree in Physical Chemistry from the Technion, Israel Institute of Technology.
Dr. Boris Oklander joined EchoSense in 2015 and has 15 years of experience in multi-disciplinary research and development. Boris leads the core of EchoSense technology development including all algorithmic research, software and hardware development activities. Boris utilizes innovative methods of signal processing, machine learning and statistics and brings a wide range of experience from the fields of sensors, mission critical systems and communication networks. Prior to joining EchoSense, Boris served as a CTO at MORE Infinity start-up company. He also served as a post-doctorate researcher at the Intelligent Systems and Networks Group at the Imperial College London and served as Senior Algorithms Engineer at the RADLive start-up company. During his military service, Boris served as R&D Team Leader in the Israeli Navy. Boris holds a Ph.D. degree in Electrical Engineering from the Technion, Israel Institute of Technology.
Michael Kharkover joined EchoSense in 2015 and has 18 years’ experience in hardware and software design, integration and software and project management. Prior to joining EchoSense, Michael served as analog engineer at Scanmaster Systems, where he designed a new generation of ultrasound hardware devices. While serving at the Life Watch medical company, Michael specialized in the development of wireless telemedicine systems and prior to this worked for Applied Materials Israel, a worldwide leading company specializing in design and manufacture systems for the semiconductor industry. Michael holds an MSc in Electronic Engineering from the Polytechnical Institute at Moldova, Kishenev.